Article Text

PDF

Novel sarcoglycan gene mutations in a large cohort of Italian patients
  1. C Boito1,
  2. M Fanin1,
  3. G Siciliano2,
  4. C Angelini1,
  5. E Pegoraro1
  1. 1Department of Neurological and Psychiatric Sciences, University of Padova, Italy
  2. 2Department of Neurosciences, University of Pisa, Italy
  1. Correspondence to:
 Dr E Pegoraro, Department of Neurological and Psychiatric Sciences, University of Padova, Via Giustiniani 5, 35128 Padova, Italy; 
 elena.pegoraro{at}unipd.it.

Statistics from Altmetric.com

The sarcoglycanopathies are a group of autosomal recessive limb girdle muscular dystrophies (LGMD) resulting from mutations in the genes encoding sarcoglycans (SG), small glycoproteins localised to the plasma membrane of muscle fibres. The sarcoglycans consist of a single transmembrane domain, a small intracellular domain, and a large extracellular domain, and their molecular weight ranges from 35 to 50 kDa. The sarcoglycan complex, which is composed of α-SG, β-SG, γ-SG, and δ-SG, is part of the dystrophin associated glycoprotein (DAG) complex, and it acts as a link between the extracellular matrix and the cytoskeleton, confers structural stability to the sarcolemma, and protects muscle fibres from mechanical stress during muscle contraction.1–3

The diseases associated with SG gene mutations (α-SG (SGCA), LGMD2D, MIM 600119; β-SG (SGCB), LGMD2E, MIM 604286; γ-SG (SGSG), LGMD2C, MIM 253700; δ-SG (SGCD), LGMD2F, MIM 601287) are rare disorders in the general population, but represent a sizeable proportion of all muscular dystrophies with normal dystrophin (about 10–20% of cases).4–8 LGM2D is the most frequent sarcoglycanopathy,9 followed by LGMD2C10 and LGMD2E,11,12 while the most rare is LGMD2F.13

Since the first description of SG gene mutation in LGMD2D,9,14 a large number of patients and mutations have been described,10–13,15–28 and correlations of genotype with clinical phenotype and protein expression have been investigated.29,30 Null mutations in any of the SG genes usually result in a severe phenotype (sometimes resembling Duchenne-like muscular dystrophy) and at the muscle biopsy level absence of the corresponding protein, whereas missense mutations have variable effects on both phenotype and protein level.

Studies of muscle biopsies from patients with null mutations in the SG genes showed that the absence of one SG subunit has consequences for the stability of the entire complex depending on which SG is mutated. Assembly of the SG complex to the membrane is dependent upon the cosynthesis of all components.31 This explains why the loss of one SG component drives the secondary loss or reduction in the other SGs, leading to destabilisation of the DAG complex, and sarcolemmal damage.3,32,33 Current pathogenetic hypotheses suggest that mutated SGs may fail to assemble because they are not competent to traffic to the sarcolemma. The failure in SG targeting may result in a rapid degradation of the mislocated protein.34

Considerable inter- and intrafamilial clinical heterogeneity have been reported in sarcoglycanopathies.14,18,35,36 The clinical spectrum of these disorders includes proximal myopathy, myoglobinuria, raised serum CK, and dilated cardiomyopathy.37–40

The diagnosis in sarcoglycanopathy patients is sometimes prompted by the detection of SG deficiency on muscle biopsy by immunofluorescence or immunoblotting analyses. The finding of SG deficiency warrants subsequent gene mutation analysis.41 Here, we report a study of SG gene mutations in a cohort of muscular dystrophy/myopathy patients of unknown aetiology selected via α-SG immunoblot analysis.

Key points

  • We studied a group of 291 limb girdle muscular dystrophy/myopathy patients, with raised CK to identify primary sarcoglycanopathy patients. Patients suitable for α-, β-, γ-, and δ-sarcoglycan gene mutation studies were selected on the basis of a decreased amount of α-sarcoglycan protein assessed by immunoblot analysis on muscle biopsies.

  • Seventeen patients (17/291, 5.8%) showed reduced α-sarcoglycan protein. Two patients (2/17, ~12%) showed complete deficiency and 15 (15/17, 88%) a partial deficiency, ranging from 5% to 50% of controls. All four α-, β-, γ-, and δ-sarcoglycan genes were screened for potential mutations in the 17 patients showing α-sarcoglycan deficiency by RT-PCR/SSCP/direct sequencing. Sarcoglycan gene mutations were detected in 12 of the 17 patients (~70%). Seven patients showed α-sarcoglycan (7/17, 41%), one β-sarcoglycan (1/17, ~6%), three γ-sarcoglycan (3/17, ~18%) and one δ-sarcoglycan (1/17, ~6%) gene mutations. Of the 14 mutations identified eight were novel.

  • Our study suggests that α-sarcoglycan immunoblotting is a sensitive screening tool to detect primary sarcoglycan deficient patients. Protein analysis must precede sarcoglycan gene analysis. The clinical phenotype in our series includes asymptomatic patients with raised CK and severe DMD-like and limb girdle muscular dystrophy presentation with or without cardiomyopathy, widening the clinical spectrum described so far in primary sarcoglycanopathies.

MATERIAL AND METHODS

Patients

About 2000 consecutive muscle biopsies from the tissue bank of the Neuromuscular Unit of the University of Padova were screened for patients meeting one or more of the following clinical and laboratory criteria: (1) raised CK (>1000 U/l); (2) progressive muscle weakness; (3) onset in the first or second decade of life; (4) normal dystrophin by immunohistochemistry and/or immunoblotting; (5) muscle histopathology consistent with a muscular dystrophy or myopathy. Two hundred and ninety-one muscle biopsies were selected and analysed with α-sarcoglycan immunoblotting.

Seventeen patients showed reduced or absent α-sarcoglycan in their muscle biopsy and were chosen for sarcoglycan gene studies. A DMD-like phenotype was assigned to those patients with onset of muscle weakness before the age of 5 years, rapid progression of weakness, and loss of ambulation before 14 years of age.

Sarcoglycan immunohistochemistry and α-sarcoglycan immunoblotting

Sarcoglycan immunohistochemistry was done as previously described.21 Briefly, patients’ muscle biopsy cryosections, 6 μm thick, were incubated for one hour at room temperature with the following antibodies: α-sarcoglycan (1:20), β-sarcoglycan (1:100), γ-sarcoglycan (1:100), and δ-sarcoglycan (1:100). All the antibodies were from Novocastra (Novocastra, Newcastle upon Tyne, UK). After three washes in PBS for five minutes each, anti-mouse cyanine-3 conjugated (1:100) (Caltag, Burlingame, CA) was used for 30 minutes. Sections were mounted with anti-fading medium. The visualisation of mounted sections was done on an Zeiss Axioskop photomicroscope. Immunolabelling of all four sarcoglycans was scored by visual inspection by two independent investigators in comparison to a normal control. The intensity of the signal was graded from normal (++++), to complete absence (− − −).

Immunoblot analysis was performed from cryosections of patients’ muscle biopsies. Briefly, muscle biopsy cryosections were dissolved in Laemmli buffer and electrophoresed on 3.5–12% polyacrylamide gels. Proteins were electroblotted to nitrocellulose membranes. Post transfer gels were stained with Coomassie blue to assess the myosin content of each muscle biopsy. The blots were air dried and immunostained with anti-α-sarcoglycan antibodies (1:800) (Novocastra, Newcastle upon Tyne, UK) for one hour. Anti-mouse biotinylated (1:1000) (Amersham, Rainham, UK) and streptavidin-horseradish peroxidase complex (1:1,000) (Amersham) antibodies were used to visualise the immunocomplexes. The blots were developed using the enhanced chemiluminescence method with luminol (ECL, Amersham). Semiquantitation of the sarcoglycan proteins was done adjusting for the protein content of each muscle biopsy.

Sarcoglycan gene mutations studies

A total of 10–50 ng of frozen muscle biopsy was homogenised using a Kinematica Polytron PT2100 homogeniser. Total RNA was extracted using Trizol (Gibco, BRL) according to the manufacturer’s instructions and stored in RNAse free water at −80°C. For cDNA synthesis about 1–2 μg of total RNA were reverse transcribed using oligo-dT primers as previously described.42 The entire coding regions of α-, β-, δ-, and γ-sarcoglycan genes were amplified by sets of overlapping primers and subjected to PCR as previously described.5,13,18 Three different SSCP (single strand conformational polymorphism) conditions were used for screening for sarcoglycan gene mutations.5 The identified conformers were reamplified using the original amplification primer and PCR conditions as previously described.5 Only the detected conformers were directly automatically sequenced (CRIBI Biotechnology Centre, University of Padova).

The sarcoglycan gene mutations identified were confirmed with the appropriate restriction endonuclease digestion if a gain or loss of restriction site was detected or with appropriate PCR primers designed to cover the mutated region, and the PCR product was size fractioned with denaturing polyacrylamide gel electrophoresis (primer sequences available upon request). Each novel mutation was assessed on 100 normal chromosomes. The autosomal recessive pattern of inheritance was confirmed in the genomic DNA of the patients’ parents when available.

RESULTS

Monoclonal antibodies directed against α-sarcoglycan were used to screen muscle biopsies of patients affected with muscular dystrophy/myopathy of unknown aetiology to identify potential primary sarcoglycanopathies. Seventeen patients showed reduced α-sarcoglycan protein by immunoblot analysis of their muscle biopsies. Two patients (2/17, ~12%) showed complete deficiency and 15 a partial deficiency, ranging from 5–50% of controls (15/17, 88%). Two patients (Nos 2 and 3, table 1) showed a doublet bands for α-sarcoglycan on immunoblotting; in both there was one band corresponding to the normal 50 kDa α-sarcoglycan and an additional band of decreased molecular weight at about 48 kDa in patient 2 and of increased molecular weight at about 55 kDa in patient 3 (fig 1).

Table 1

Clinical and molecular data in sarcoglycanopathy patients

Figure 1

Immunoblot analysis of muscle biopsies from two α-sarcoglycan deficient patients showing partial α-sarcoglycan deficiency. Shown is α-sarcoglycan immunoblot analysis of patients 2 and 4 and control muscle containing normal α-sarcoglycan. The lower panel is the corresponding post-transfer gel stained with Coomassie Blue to visualise the myosin heavy chain protein used for normalising myofibre protein content of samples. A doublet of bands is shown for α-sarcoglycan in patient 2; the bottom band (arrow) corresponds to the 50 kDa normal size α-sarcoglycan protein, and the top band to higher molecular weight α-sarcoglycan positive material. This band may represent a degradation product owing to the instability of the dystrophin-glycoprotein complex following sarcoglycan deficiency itself. Less than 20% of normal control α-sarcoglycan is detectable in patient 4’s muscle biopsy (values adjusted to the protein content of muscle samples).

Immunohistochemistry of all four sarcoglycan proteins showed consistent results in α-, β-, and δ-sarcoglycanopathy patients (table 1). In γ-sarcoglycanopathy, the complete absence of γ-sarcoglycan was associated with a variable reduction of the other three proteins (table 1). Patients showing by immunoblotting a reduction of α-sarcoglycan in their muscle biopsy ranging from 0 to 20% of normal had by α-sarcoglycan immunohistochemistry a variable reduction of labelling ranging from absent to moderate (table 1). The only two patients showing by immunoblot more than 20% of the protein (Nos 2 and 3, table 1) had a mild or moderate reduction of labelling of α-sarcoglycan (table 1).

All four α-, β-, γ-, and δ-sarcoglycan genes were screened for pathogenetic mutations in the 17 patients showing α-sarcoglycan deficiency. Sarcoglycan gene mutations were detected in 12 of the 17 patients (~70%). Seven patients showed α-sarcoglycan (7/17, 41%), one β-sarcoglycan (1/17, ~6%), three γ-sarcoglycan (3/17, ~18%), and one δ-sarcoglycan (1/17, ~6%) gene mutations (table 1). Family history, clinical presentation, and sarcoglycan gene and protein data for each patient are summarised in table 1.

α-sarcoglycan

Nine α-sarcoglycan gene mutations were identified and five of them were novel. All of them were located in the extracellular, amino-terminal domain of the protein. Seven were missense changes (in six patients), one was a single base pair out of frame insertion, and one mutation altered the acceptor splice site of intron 5 (table 1). Twenty-seven percent of the mutated chromosomes (3/11) had variations in exon 3 (table 1).

Patients 1 and 5 showed complete absence of α-sarcoglycan. Patient 1 also had a complete loss of the sarcoglycan complex, and a severe phenotype with early onset (4 years) and loss of ambulation at 12 years of age, while patient 5 is still ambulant with bilateral support at 43 years of age (table 1). Patient 1 harboured a complex mutation affecting the acceptor splice site of exon 6, a single base pair deletion at position −1, and an in cis point mutation at position −2 (IVS −1delG/-2A>G) abolishing the correct splicing of exon 5 to exon 6. Both mutations were homozygous. SSCP analysis using a forward primer in exon 5 and a reverse primer in exon 7 of the α-sarcoglycan coding sequence showed a homozygous out of frame deletion of exon 6. SSCP analysis of exon 6 flanking splice sites showed in this patient a −1 delG/-2 A>G of the acceptor splice site of intron 5. The mutations in the intron did not cause any loss or gain of a restriction site enzyme and SSCP using the original primer set was done in the patient, her parents, and 100 normal chromosomes. SSCP analysis showed that the same mutation was inherited from both parents. In this patient, an insertion of 80 bp at the end of intron 6 was identified owing to the use of a cryptic splice site.

Of the remaining five patients, three had a LGMD phenotype (patients 2, 4, and 6) and two presented with calf hypertrophy and raised CK level. Interestingly, in two patients (Nos 2 and 3) harbouring heterozygous missense changes, α-sarcoglycan was mildly reduced (about 40% of controls), but on α-sarcoglycan immunoblotting extra bands at about 55 kDa and 48 kDa were detected (table 1, fig 1). Thus, of the seven patients studied, two were compound heterozygous (patients 3 and 4), two were homozygous (patients 1 and 5), and in three only one α-sarcoglycan mutation was identified (patients 2, 6, and 7) (table 1).

β-sarcoglycan

β-sarcoglycan gene mutations were identified in only one patient (table 1, patient 8). This patient showed a novel, homozygous out of frame duplication spanning nucleotide 21 to nucleotide 52 of the β-sarcoglycan coding sequence (accession No XM_003553). This duplication encompassed 22 bp before the ATG and 10 bp in exon 1 of the β-sarcoglycan gene, and caused a frameshift with a stop codon 25 amino acids downstream of the mutation (table 1). This patient was from a consanguineous family and presented at 7 years of age with mild muscle weakness, which has progressed since then. At 21 years the patient developed a dilated cardiomyopathy. At 37 years of age the patient showed a marked waddling gait, with proximal muscle weakness in the upper and lower limb.

γ-sarcoglycan

Three patients had γ-sarcoglycan gene mutations. Patient 9 was homozygous for the C283T variation found in Gypsies, patient 10 was a compound heterozygote for a novel nonsense change (L43X) and a single thymine deletion at position 517 of the γ-sarcoglycan gene, and patient 11 was heterozygous for an out of frame single thymine insertion at position 87. Interestingly, the 128 T>G resides in the transmembrane domain of the γ-sarcoglycan protein. Clinical phenotype was severe DMD-like in two of the three patients (patients 9 and 11), and only calf hypertrophy was detected at 7 years of age in patient 10. Patient 11 also had a dilated cardiomyopathy (table 1). All these patients showed a complete absence of γ-sarcoglycan on immunoblotting.

δ-sarcoglycan

In one patient a homozygous, novel, missense mutation (R198P) was identified in exon 7 of the δ-sarcoglycan gene. The clinical presentation and disease progression was compatible with a DMD-like phenotype. The patient lost ambulation at 13 years of age (fig 2).

Figure 2

Screening of the δ-sarcoglycan coding sequence for potential mutations by single stranded conformational polymorphism (SSCP) showed a G593C homozygous nucleotide change resulting in a R198P amino acid change in patient 12. In the top panel, SSCP analysis of RT-PCR product for primer set 435F-748R showed a unique conformer in patient 12. Direct sequencing of the aberrant conformer showed a G to C nucleotide change at position 593 of the δ-sarcoglycan coding sequence (middle panel) resulting in an arginine to proline amino acid change at position 198 of the α-sarcoglycan protein. Nucleotide change G593G resulted in a loss of MpsI restriction enzyme site. Primers were designed to amplify exon 7 of the δ-sarcoglycan gene and the PCR product was digested with MpsI. Digestion fragments were present in 100 control chromosomes, in none of patient 12’s chromosomes, and only in one of the patient’s parents’ and unaffected sister’s chromosomes (heterozygous mutation) (bottom panel).

All changes in the four genes were confirmed in the patients’ genomic DNA. At least 100 normal chromosomes were tested for each DNA change by either restriction digestion or by SSCP analysis. None of the changes were detected in the control chromosomes.

DISCUSSION

We have studied molecularly 17 patients showing partial or complete deficiency of α-sarcoglycan on muscle biopsy. We have ascertained these patients based on α-sarcoglycan immunoblotting results.

Sarcoglycan gene mutations are a well known cause of four forms of limb girdle muscular dystrophies. Identification of gene mutations and their correlations with clinical phenotype have been extensively studied. The clinical presentation of the various sarcoglycanopathies rarely points to a specific gene defect; most of the patients present with proximal muscle weakness, and variability in clinical severity and age of onset have been reported in all four sarcoglycanopathies. As the disease progresses, the selectivity of proximal muscle weakness is lost and all muscle groups except for the facial, ocular, and velopharyngeal groups are involved.7 Molecular studies of the four sarcoglycan genes are necessary when the primary abnormality needs to be established.

α-sarcoglycan immunohistochemistry in muscle biopsy cryosections is often used to screen for sarcoglycan deficiency based on the assumption that the primary loss of any component of the sarcoglycan complex will lead to the secondary deficiency of all the others. In a previous study using α-sarcoglycan immunofluorescence to identify sarcoglycanopathy patients, we reported a mutation detection rate of about 57% in complete or partial α-sarcoglycan deficiency cases.5 Here we chose to use α-sarcoglycan immunoblotting to screen a large series of undiagnosed limb girdle muscular dystrophy/myopathy patients assuming that a slight deficiency of α-sarcoglycan may be not detected by immunohistochemistry. This assumption proved to be correct in our series, where at least one patient would not have been ascertained by α-sarcoglycan immunohistochemistry alone (patient 2, table 1). Indeed, of 17 patients showing partial or complete α-sarcoglycan deficiency on their muscle biopsies we were able to identify gene mutations in about 70% of them (12/17). Of the five mutation negative patients, four had α-sarcoglycan reduced to 40 to 50% of controls by immunoblot and were scored as normal by immunohistochemistry of all four sarcoglycan proteins. It is very likely that these patients have a mild, secondary reduction of the sarcoglycan complex owing to an as yet unknown primary gene defect. The fifth patient is more difficult to interpret. This patient had a severe reduction not only of α-sarcoglycan, but also of the other components of the complex, suggesting a primary sarcoglycanopathy. The inability to detect causative gene mutations may be because of the incomplete sensitivity of our mutation detection technique or rare mutations in the promoter or intron sequences.

α-sarcoglycan immunoblotting identified two patients (patients 2 and 3) with a doublet of bands. At least in one case (patient 3) mutations in both α-sarcoglycan alleles were identified, but no underlying genetic causes for the additional band were detected. Moreover, in both patients, α-sarcoglycan cDNA was completely sequenced and no additional mutations were identified. A possible explanation is that this band may represent a degradation product owing to the instability of the dystrophin-glycoprotein complex following sarcoglycan deficiency itself, as also suggested by the lack of abnormal RT-PCR product consistent with an insertion or deletion.

In 12 patients, 14 different sarcoglycan gene mutations were identified. Novel mutations (8/14) were identified in all four sarcoglycan genes and confirmed that mutation type (missense versus nonsense) and site (extracellular versus transmembrane domain) are not predictive of the severity of the clinical phenotype. For example, patient 10 who harboured two null mutations in the γ-sarcoglycan gene, one in the extracellular and one in the transmembrane domain, has a milder phenotype than patient 9 who harboured a homozygous missense mutation in the extracellular domain of γ-sarcoglycan. Patient 10 was diagnosed at 4 years of age because of asymptomatic raised serum CK found on routine testing followed by muscle biopsy. At 7 years of age the patient is still asymptomatic and shows only slight calf hypertrophy. Conversely, patient 9 presented at 4 years with proximal muscle weakness, and at 8 years of age the patient had difficulty in climbing stairs and raising herself from the floor and had a marked proximal weakness mostly in the upper limbs. The last clinical evaluation was done at 14 years and showed a marked waddling gait with inability to raise herself from the floor and to lift her arms.

All the mutations identified in the α-sarcoglycan gene (eight changes) were in the extracellular domain of the protein and mutations in exon 3 accounted for about 22% of the mutations identified (2/9), as previously reported.7 The clinical phenotype in our genetically proven α-sarcoglycan patients varied between high CK with mild calf hypertrophy to a DMD-like presentation, confirming clinical heterogeneity in this subset of patients. The amount of residual α-sarcoglycan protein may affect clinical severity; however, patient 7, with 5% of residual α-sarcoglycan protein, showed only calf hypertrophy at 14 years, while patient 2 with 40% of the protein presented at 4 years with difficulties in climbing stairs and raising himself from the floor.

The only β-sarcoglycan null gene mutation we identified was located in the cytoplasmic domain of the protein and was associated with a relatively mild phenotype. Interestingly, this patient had a dilated cardiomyopathy suggesting that β-sarcoglycan gene mutations result in a reduced capacity of the sarcoglycan complex to transmit force to the extracellular matrix.39,43

Four mutations were identified in the γ-sarcoglycan gene in three patients. γ-sarcoglycan protein was completely absent from all three patients’ muscle biopsy; however, a single patient had a mild phenotype suggesting that a defective sarcoglycan complex lacking some components may still be assembled and attached to the plasma membrane, or a single sarcoglycan may be bound to the membrane by an unknown mechanism.44 δ-sarcoglycanopathy is the rarest sarcoglycanopathy with only a few mutation reported.13,21,23,26,45 We identified a novel homozygous missense mutation in a patient presenting with a severe DMD-like phenotype who lost ambulation at 13 years of age.

In conclusion, our study suggests that protein analysis should precede sarcoglycan gene analysis and that screening for common mutations is worthwhile only in a specific patient population.

Acknowledgments

This work was supported by a grant from the Italian Telethon (No 1114), Telethon bank (No GTF02009), and MURST (No 2001068328).

REFERENCES

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.